Raised S.B. No. 188
Session Year 2022
 


AN ACT REQUIRING BRAND NAME PRESCRIPTION DRUG MANUFACTURERS TO PROVIDE SAMPLES OF BRAND NAME DRUGS TO GENERIC PRESCRIPTION DRUG MANUFACTURERS.

To promote competition in the prescription drug market by allowing developers of generic drugs and biosimilar products to obtain reference samples.

Introduced by:
General Law Committee

 New today  2-4 days old  5 days & older
  View or Add Notes to SB-188

Add Notes to SB-188

Go To My Bills


This bill is in My Bills.
Do you wish to go to My Bills?

Co-sponsors for Amendment LCO:

Bill History

 Date Action Taken
 4/7/2022Referred by Senate to Committee on Judiciary
 3/30/2022(LCO)File Number 214
 3/30/2022Senate Calendar Number 170
 3/30/2022Favorable Report, Tabled for the Calendar, Senate
 3/30/2022(LCO)Reported Out of Legislative Commissioners' Office
 3/24/2022(LCO)Referred to Office of Legislative Research and Office of Fiscal Analysis 03/29/22 5:00 PM
 3/16/2022(LCO)Filed with Legislative Commissioners' Office
 3/15/2022(GL)Joint Favorable
 2/25/2022Public Hearing 03/01
 2/24/2022Referred to Joint Committee on General Law

Co-sponsors of SB-188

NOTE: Please direct all inquiries regarding the status of bills to the Office of the House Clerk and/or Senate Clerks' Office.